No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
SFM240719P90000
- 7.40
- -0.90-10.84%
15min DelayClose Jun 28 16:00 ET
7.40High7.40Low
7.40Open8.30Pre Close1 Volume2 Open Interest90.00Strike Price740.00Turnover27.96%IV1.27%PremiumJul 19, 2024Expiry Date6.34Intrinsic Value100Multiplier19DDays to Expiry1.06Extrinsic Value100Contract SizeAmericanOptions Type-0.8695Delta0.0470Gamma12.77Leverage Ratio-0.0219Theta-0.0240Rho-11.11Eff Leverage0.0401Vega
Intraday
- 5D
- Daily
News
Sprouts Farmers Market Is Maintained at Neutral by UBS
Sprouts Farmers Market Is Maintained at Neutral by UBS
Express News | Sprouts Farmers Market Inc : UBS Raises Target Price to $94 From $68
UBS Maintains Sprouts Farmers Market(SFM.US) With Hold Rating, Raises Target Price to $94
UBS analyst Mark Carden maintains $Sprouts Farmers Market(SFM.US)$ with a hold rating, and adjusts the target price from $68 to $94.According to TipRanks data, the analyst has a success rate of 65.9%
Zacks Industry Outlook Highlights Performance Food, Sprouts Farmers Market, SpartanNash and Farmer Bros
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $4,400 Today
Sprouts Farmers Market (NASDAQ:SFM) has outperformed the market over the past 5 years by 21.94% on an annualized basis producing an average annual return of 34.93%. Currently, Sprouts Farmers Market h
Small-cap, Buy-rated Stocks With Positive Estimate Revision Factors - BofA
Comments
Today, we are looking for targets to buy Mon. after Fri's massacre.
$Summit Therapeutics(SMMT.US$
Lung cancer Pharma company's new drug shows tangible improvement over the only other medication for the most common deadly case of lung cancer.
Fundamentals are solid. The PCB is overbought, though. We set our target for $13, but gonna watch this one close. Pharma be fickle.
$A10 Networks(ATEN.US$
I feel is strongest of the day. They make software for things like data-center optimization. Wonde...
$Summit Therapeutics(SMMT.US$
Lung cancer Pharma company's new drug shows tangible improvement over the only other medication for the most common deadly case of lung cancer.
Fundamentals are solid. The PCB is overbought, though. We set our target for $13, but gonna watch this one close. Pharma be fickle.
$A10 Networks(ATEN.US$
I feel is strongest of the day. They make software for things like data-center optimization. Wonde...
4
Investors' belief in Sprouts Farmers Market's continued market outperformance likely causes its high P/E ratio. However, with forecast growth only matching the wider market, the high P/E ratio may be unjustified, risking a share price decline. The current earnings growth level may also pressure the share price.
1
Significant insider selling at Sprouts Farmers Market may suggest insiders believe the shares are overpriced. Despite profitability and growth, the absence of insider buying and low insider ownership could caution potential investors.
Sprouts, a leading specialty grocer, has shown resilience despite grocery business challenges. Its quarterly performance was boosted by higher-than-anticipated same-store sales growth and fewer new store openings. The company's same-store sales growth and annual earnings forecast surpassed Wall Street's predictions. The stock rose 3.3% post-reporting.
1
The market's opinion of the business has improved over the past five years due to its growth track record. The stock's recent performance and strong share price momentum suggest it may be worth a closer look.
Read more